Glycaemic control in people with diabetes following acute myocardial infarction

Diabetes Res Clin Pract. 2023 May:199:110644. doi: 10.1016/j.diabres.2023.110644. Epub 2023 Mar 29.

Abstract

Diabetes is a highly prevalent disease associated with considerable cardiovascular end organ damage and mortality. Despite significant changes to the management of acute myocardial infarction over the last two decades, people with diabetes remain at risk of complications and mortality following a myocardial infarct for a multitude of reasons, including increased coronary atherosclerosis, associated coronary microvascular dysfunction, and diabetic cardiomyopathy. Dysglycaemia causes significant endothelial dysfunction and upregulation of inflammation within the vasculature and epigenetic changes mean that these deleterious effects may persist despite subsequent efforts to tighten glycaemic control. Whilst clinical guidelines advocate for the avoidance of both hyper- and hypoglcyaemia in the peri-infarct period, the evidence base is lacking, and currently there is no consensus on the benefits of glycaemic control beyond this period. Glycaemic variability contributes to the glycaemic milieu and may have prognostic importance following myocardial infarct. The use of continuous glucose monitoring means that glucose trends and parameters can now be captured and interrogated, and its use, along with newer medicines, may provide novel opportunities for intervention after myocardial infarction in people with diabetes.

Keywords: Continuous glucose monitoring; Diabetes technology; Ischaemic heart disease; Type 1 diabetes; Type 2 diabetes.

Publication types

  • Review

MeSH terms

  • Blood Glucose
  • Blood Glucose Self-Monitoring
  • Diabetes Mellitus, Type 2* / complications
  • Glucose
  • Glycemic Control
  • Humans
  • Hyperglycemia* / complications
  • Myocardial Infarction*

Substances

  • Blood Glucose
  • Glucose